Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., announced on May 22, 2025, the completion of a Phase I strategic research and literature synthesis for EL-22. EL-22 is its first-in-class oral myostatin-engineered probiotic.
The analysis, conducted in collaboration with Yuva Biosciences and supported by AI-based scientific review technology from Yuva Biosciences’ MitoNova™, provided valuable insights into EL-22’s proposed mechanism of action. This will help guide further exploration into its potential to address critical unmet needs in muscle-wasting conditions.
EL-22 is designed to induce a targeted immune response against myostatin, a key negative regulator of muscle growth, offering a convenient oral delivery method. The review confirmed EL-22's potential in GLP-1-associated atrophy and age-related sarcopenia.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.